What are the outcomes for patients with relapsed Wilms tumor in the UK?

Wilms tumor is the most common type of kidney cancer in children. While many cases are successfully treated, some patients experience a relapse, which is when the cancer returns after initial treatment. Outcomes for these patients can vary based on the specific treatment protocols used and the timing of the relapse.

What the research says

A clinical trial conducted in the United Kingdom specifically for relapsed Wilms tumor (UKW-R) aimed to improve survival rates through a risk-stratified protocol. In this study, patients were divided into groups based on their initial treatment and how long it took for the cancer to return. The trial reported that 63% of these patients achieved four-year event-free survival, while 68% reached the four-year overall survival mark ².

Research also highlights that outcomes can differ significantly depending on the risk level of the relapse. For example, in a different study of relapsed tumors with favorable histology (favorable tissue types), patients classified as standard-risk had an 82.4% four-year event-free survival rate and a 93.3% overall survival rate. In contrast, those categorized as high-risk or very high-risk had lower rates, with 32.6% event-free survival and 58.3% overall survival ⁵.

While most cases of Wilms tumor occur in children, it can also appear in adults. These cases are rare and may present different challenges for doctors because they can look like other types of kidney cancer ¹. Additionally, some patients may experience a very late recurrence, sometimes decades after the initial diagnosis ⁴.

What to ask your doctor

• What is my child's specific risk category for relapsed Wilms tumor?
• How does the UKW-R trial data apply to my child's specific case?
• What are the expected survival rates based on our current treatment plan?
• Are there specific surgical or chemotherapy options available if a relapse occurs?